Work

New Life of Topoisomerase I Inhibitors as Antibody–Drug Conjugate Warheads

Year: 2023

Type: article

Abstract: Antibody-drug conjugates (ADC) allow the delivery of cytotoxic chemotherapeutic agents to tumors. Two ADC delivering topoisomerase I (TOP1) poisons (Enhertu and Trodelvy) have recently been FDA-approved for Her2- and Trop2-expressing solid tumors. In a recent study, a TOP1-anti B7-H4 ADC was described and shown to be synergistic with a novel PARP1-selective inhibitor. See related article by Kinneer et al., p. 1086.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-22-3640

Authors: Yves Pommier, Anish Thomas

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze